

Takayama Koichi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6091849/publications.pdf>

Version: 2024-02-01

8
papers

270
citations

1306789

7
h-index

1588620

8
g-index

8
all docs

8
docs citations

8
times ranked

342
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1362.	1.0	102
2	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2244-2256.	3.2	75
3	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	24
4	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. <i>Cancer</i> , 2022, 128, 2025-2035.	2.0	18
5	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2022, 12, 423.	1.3	17
6	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2033.	1.0	13
7	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. <i>Cancer Letters</i> , 2021, 522, 119-128.	3.2	13
8	Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. <i>Diagnostics</i> , 2021, 11, 2170.	1.3	8